<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36942">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02069821</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_EXA_101</org_study_id>
    <nct_id>NCT02069821</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interactions Between Amlodipine Besylate/Valsartan and Atorvastatin in Healthy Male Subjects</brief_title>
  <official_title>An Open-label, Multiple-dosing, Two-arms, One-sequence Study to Evaluate the Safety and Pharmacokinetics After Co-administration of Exforge® (Amlodipine Besylate/Valsartan) and Lipitor® (Atorvastatin Ca) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the pharmacokinetic interactions between amlodipine
      besylate/valsartan and atorvastatin single or co-administered in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>To Evaluate PK interaction of amlodipine and valsartan</measure>
    <time_frame>from pre dosing to 24hr post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUCss,τ, Css,max</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Evaluate PK interaction of atorvastatin and 2-OH atorvastatin</measure>
    <time_frame>from pre dosing to 24hr post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUCss,τ, Css,max</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate PK interaction of amlodipine and valsartan</measure>
    <time_frame>from pre dosing to 24hr post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>tss,max, CLss/F, Css,min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate PK interaction of atorvastatin and 2-OH atorvastatin</measure>
    <time_frame>from pre dosing to 24hr post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>tss,max, CLss/F, Css,min</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single administration : amlodipine/valsartan 10/160mg, qd, 10days(oral)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single administration : atorvastatin  40mg, qd, 7days(oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combination administration</intervention_name>
    <description>combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male volunteers in the age between 20 and 45 years old

          2. The weight is over 55kg and is not exceed ±20% of ideal weight Ideal weight = [height
             -100]*0.9

          3. Subjects with no history of any significant chronic disease

          4. Judged to be in good health on the basis of routine laboratory data obtained prior to
             study drug administration

          5. Willing to adhere to protocol requirements and sign a informed consent form

        Exclusion Criteria:

          1. Subjects with Symptoms of acute disease within 28days prior to study medication
             dosing

          2. Subjects with a history of gastrointestinal diseases which might significantly change
             ADME of medicines

          3. Subjects with a history of clinically significant allergies including drug allergies
             or anaphylaxis to amlodipine, valsartan and/or atorvastatin

          4. Subjects with a history of myopathy

          5. Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase
             deficiency or glucose-galactose malabsorption

          6. Subject with the mean blood pressure of siDBP ≥ 150 mmHg or ≤ 90 mmHg and/or siSBP ≥
             95 mmHg or ≤ 50 mmHg at the screening visit

          7. Subjects with abnormal HDL-cholesterol(&lt;35mg/dL)

          8. Subjects with abnormal of serum potassium concentration (&lt;3.4 mEq/L of &gt;5.5 mEq/L in
             screening visit)

          9. Subjects with a history of drug abuse

         10. Subjects taking inducer or inhibitor of drug metabolism enzyme such as barbital
             within 28days prior to study medication dosing

         11. Subjects who have received any drugs that might confound the results of the trial
             based on medical judgement by investigators within 14days prior to drug
             administration and OTC or vitamin within 7days prior to drug administration

         12. Participated in a previous clinical trial within 60 days prior to dosing

         13. Donated blood within 60 days prior to dosing

         14. Subjects with a history of alcohol abuse(over 21 units/week, 1 unit = 10 g of pure
             alcohol) or is difficult to stop drinking within study

         15. Subjects have ever smoked over 10 cigarette per day within 3 months prior to drug
             administration

         16. Subjects with a history of caffeine abuse or or is difficult to stop drinking within
             study

         17. Subjects with biliary obstruction

         18. Subjects with hepatic dysfunction (AST or ALT &gt;3 times to accepted normal range)

         19. Subjects with moderate renal dysfunction (creatinine clearance (CLcr) &lt; 30mL/min)

         20. Subjects considered as unsuitable based on medical judgement by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hong Jang Hee, assistant professor</last_name>
    <phone>+82-42-280-8718</phone>
    <email>boniii@cnu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chungnam national university hospital</name>
      <address>
        <city>Daejeon</city>
        <state>Jung-gu</state>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hong Jang Hee, assistant professor</last_name>
      <phone>+82-42-280-8718</phone>
      <email>boniii@cnu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>February 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Amlodipine, valsartan drug combination</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
